Literature DB >> 122522

Penicillin-netilmicin synergism against Streptococcus faecalis.

O M Korzeniowski, C Wennersten, R C Moellering, M A Sande.   

Abstract

The combination of penicillin plus netilmicin was synergistic in vitro against 28 strains of Streptococcus faecalis and compared favorably with penicillin in combination with gentamicin. Similarly, penicillin plus netilmicin was as effective as penicillin plus gentamicin in the therapy of 67 rabbits with enterococcal endocarditis produced with a streptomycin-susceptible (S) or a streptomycin-resistant (R) strain of S. faecalis. After 5 days of infection, control rabbits had bacterial titers of 10(10) colony-forming units (CFU)/g of vegetation. Those treated with penicillin plus netilmicin had mean titers of 10(5.2) and 10(5.1) CFU/g for S and R strains, respectively, and those treated with penicillin plus gentamicin had mean valve titers of 10(5.8) CFU/g for both strains. After 10 days of therapy, mean valve titers with penicillin plus netilmicin were 10(3.8) and 10(4.7) CFU/g, and with penicillin plus gentamicin they were 10(4.5) and 10(5.4) CFU/g for S and R strains, respectively. Thus, if netilmicin proves to be less toxic than other aminoglycoside antibiotics, it may have potential usefulness in the therapy of enterococcal endocarditis.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 122522      PMCID: PMC352259          DOI: 10.1128/AAC.13.3.430

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  18 in total

1.  Identification of streptococci: use of lysozyme and Streptomyces albus filtrate in the preparation of extracts for Lancefield grouping.

Authors:  B K Watson; R C Moellering; L J Kunz
Journal:  J Clin Microbiol       Date:  1975-03       Impact factor: 5.948

2.  Penicillin and gentamicin therapy for enterococcal infections.

Authors:  A J Weinstein; R C Moellering
Journal:  JAMA       Date:  1973-02-26       Impact factor: 56.272

3.  Simplified, accurate method for antibiotic assay of clinical specimens.

Authors:  J V Bennett; J L Brodie; E J Benner; W M Kirby
Journal:  Appl Microbiol       Date:  1966-03

4.  In vitro activity of netilmicin.

Authors:  J A Smith; J R Morgan; M Mogyoros
Journal:  Antimicrob Agents Chemother       Date:  1977-02       Impact factor: 5.191

5.  Antibiotic synergism of enterococci. Relation to inhibitory concentrations.

Authors:  H D Standiford; J B De Maine; W M Kirby
Journal:  Arch Intern Med       Date:  1970-08

6.  Biological activity of netilmicin, a broad-spectrum semisynthetic aminoglycoside antibiotic.

Authors:  G H Miller; G Arcieri; M J Weinstein; J A Waitz
Journal:  Antimicrob Agents Chemother       Date:  1976-11       Impact factor: 5.191

7.  Antimicrobial therapy of experimental enterococcal endocarditis.

Authors:  E W Hook; R B Roberts; M A Sande
Journal:  Antimicrob Agents Chemother       Date:  1975-11       Impact factor: 5.191

8.  Antimicrobial therapy of experimental endocarditis caused by Staphylococcus aureus.

Authors:  M A Sande; M L Johnson
Journal:  J Infect Dis       Date:  1975-04       Impact factor: 5.226

9.  Recognition of group D streptococcal species of human origin by biochemical and physiological tests.

Authors:  R R Facklam
Journal:  Appl Microbiol       Date:  1972-06

10.  Penicillin-tobramycin synergism against enterococci: a comparison with penicillin and gentamicin.

Authors:  R C Moellering; C Wennersten; A J Weinstein
Journal:  Antimicrob Agents Chemother       Date:  1973-04       Impact factor: 5.191

View more
  10 in total

Review 1.  In vivo antibiotic synergism: contribution of animal models.

Authors:  B Fantin; C Carbon
Journal:  Antimicrob Agents Chemother       Date:  1992-05       Impact factor: 5.191

Review 2.  Beta lactam antibiotic monotherapy versus beta lactam-aminoglycoside antibiotic combination therapy for sepsis.

Authors:  Mical Paul; Adi Lador; Simona Grozinsky-Glasberg; Leonard Leibovici
Journal:  Cochrane Database Syst Rev       Date:  2014-01-07

3.  Importance of the aminoglycoside dosing regimen in the penicillin-netilmicin combination for treatment of Enterococcus faecalis-induced experimental endocarditis.

Authors:  B Fantin; C Carbon
Journal:  Antimicrob Agents Chemother       Date:  1990-12       Impact factor: 5.191

4.  Decision making under risk: framing effects in pigeon risk preferences.

Authors:  Wilson D Clayton; Shelby M Brantley; Thomas R Zentall
Journal:  Anim Cogn       Date:  2022-03-16       Impact factor: 3.084

5.  Simulated human serum profiles of one daily dose of ceftriaxone plus netilmicin in treatment of experimental streptococcal endocarditis.

Authors:  M Blatter; U Fluckiger; J Entenza; M P Glauser; P Francioli
Journal:  Antimicrob Agents Chemother       Date:  1993-09       Impact factor: 5.191

Review 6.  Versatility of aminoglycosides and prospects for their future.

Authors:  Sergei B Vakulenko; Shahriar Mobashery
Journal:  Clin Microbiol Rev       Date:  2003-07       Impact factor: 26.132

7.  Synergistic activity of ceftriaxone combined with netilmicin administered once daily for treatment of experimental streptococcal endocarditis.

Authors:  P B Francioli; M P Glauser
Journal:  Antimicrob Agents Chemother       Date:  1993-02       Impact factor: 5.191

8.  Antimicrobial activity of gentamicin in experimental enterococcal endocarditis.

Authors:  P M Sullam; M G Täuber; C J Hackbarth; M A Sande
Journal:  Antimicrob Agents Chemother       Date:  1985-02       Impact factor: 5.191

9.  Effects of medium and inoculum variations on screening for high-level aminoglycoside resistance in Enterococcus faecalis.

Authors:  D F Sahm; C Torres
Journal:  J Clin Microbiol       Date:  1988-02       Impact factor: 5.948

10.  Resistance to antibiotic synergism in Streptococcus faecalis: further studies with amikacin and with a new amikacin derivative, 4'-deoxy, 6'-N-methylamikacin.

Authors:  S B Calderwood; C Wennersten; R C Moellering
Journal:  Antimicrob Agents Chemother       Date:  1981-04       Impact factor: 5.191

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.